Home
FDA Calendar
About & More
Testimonials
Useful Links
Our Disclaimer
Updates and Roadmap
Contribute
Create Company Profile
Create Drug Profile
Browse
Contact
FDA Calendar for Array BioPharma Inc. (ARRY)
Login Now
|
Register (free)
Array BioPharma Inc. (Array) is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer, inflammatory and metabolic diseases. In addition, pharmaceutical and biotechnology companies collaborate with the Company to discover and develop drug candidates across a range of therapeutic areas. The Company has seven wholly owned programs in its development pipeline: ARRY-403, a glucokinase activator for Type 2 diabetes; ARRY-162, a MEK inhibitor for rheumatoid arthritis and cancer; ARRY-380, an ErbB-2 inhibitor for breast cancer; ARRY-520, a KSP inhibitor for acute myeloid leukemia and multiple myeloma; ARRY-614, a p38/Tie 2 dual inhibitor for myelodysplastic syndrome; ARRY-543, an ErbB family (ErbB-2 / EGFR) inhibitor for solid tumors, and ARRY-797, a p38 inhibitor for subacute pain and cancer supportive care indications.
Around The Net
Latest News
Twitter Stream
Yahoo Message Board
Google Message Board
You are reading news provided by a variety of web sources.
ZNGA, AMLN, YOKU, RAX Among Charts to Watch
2 day(s)
14 Rallying Biotech Stocks Being Snapped Up By Insiders
3 day(s)
KTCC, MDVN, STX, BVSN Among Charts to Watch
3 day(s)
Colorado stocks: Gasco up 10%, Ascent Solar up 9%
3 day(s)
Array Biopharma Incorporated (ARRY) Downgraded by Zacks Investment Research
4 day(s)
Drug Pipeline
Drug Name
Type Of Drug
FDA Status
Drug Phase
This company currently does not have any drugs. If you would like to create one please
click here
.
Events
No future events listed at this time, please check back later.
Outcome
Past Events
Add New Event
In order to write a comment you must first login.
Login
or
Register
(for free!)
Add Event
Important Links
No links found.
Add New Link
In order to write a comment you must first login.
Login
or
Register
(for free!)
Add Link
ARRY
$3.01
0.00 0.00%
2/3/2012 4:00:00 PM
Sponsors
Other Links
Corporate Website
Analyst Estimates (MarketWatch)
CNN Money
Google Finance
Guru Focus
Major Holders
MSN Money
SEC Filings (EDGAR Online)
Seeking Alpha
Yahoo! Finance